Selective inhibition of [D-ALA(2), GLU(4)]deltrophin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor Journal Article


Authors: Bilsky, E. J.; Bernstein, R. N.; Pasternak, G. W.; Hruby, V. J.; Patel, D.; Porreca, F.; Lai, J.
Article Title: Selective inhibition of [D-ALA(2), GLU(4)]deltrophin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid delta receptor
Abstract: Evidence in vivo has suggested the existence of subtypes of the δ opioid receptor (DOR), which have been termed δ1 and δ2. These proposed DOR subtypes are thought to be activated by [D-Pen2, D- Pen5]enkephalin (DPDPE, δ1) and [D-Ala2, Glu4]deltorphin (δ2). Recent work in which an antisense oligodeoxynucleotide (oligo) to a cloned DOR was administered by the intrathecal (i.th.) route has demonstrated a reduction in the antinociceptive actions of both i.th. DPDPE and [D-Ala2, Glu4]deltorphin, but not of [D-Ala2, NMPhe4, Gly-ol]enkephalin (DAMGO, μ agonist) in mice. The present investigation has extended these observations by administering the same DOR antisense oligo sequence by the intracerebroventricular (i.c.v.) route and evaluating the antinociceptive actions of i.c.v. agonist selective for δ, μ and κ receptors. I.th. treatment with DOR antisense oligo, but not mismatch oligo, significantly inhibited the antinociceptive actions of both i.th. DPDPE and [D-Ala2, Glu4deltorphin but not of i.th. DAMGO or U69, 593 (κ agonist), confirming previous data. In contrast, i.c.v. DOR antisense oligo, but not mismatch oligo, seletively inhibited the anitinociceptive response to i.c.v. [D-Ala2, Glu4]deltorphin without altering the antinociceptive actions of i.c.v. DPDPE, DAMGO or U69,593. The data suggest that the cloned DOR corresponds to that pharmacologically classified as δ2 and further, suggest that this δ receptor subtype may play a major role in eliciting spinal δ-mediated antinociception. © 1994.
Keywords: controlled study; unclassified drug; nonhuman; mouse; animal; mice; drug inhibition; animal experiment; mice, inbred icr; drug selectivity; drug synthesis; central nervous system; molecular sequence data; spinal cord; base sequence; analgesics; oligopeptides; injections, spinal; enkephalin[2,5 dextro penicillamine]; oligonucleotides, antisense; nociceptors; pyrrolidines; delta opiate receptor; receptor subtype; injections, intraventricular; enkephalin, ala(2)-mephe(4)-gly(5)-; receptors, opioid, delta; antinociception; antisense oligodeoxynucleotide; enkephalin[2 dextro alanine 4 methylphenylalanine 5 glycine]; opiate agonist; intracerebroventricular drug administration; antisense oligodeoxynucleotides; male; article; enkephalins; enkephalin, d-penicillamine (2,5)-; intrathecal drug administration; n methyl n [7 (1 pyrrolidinyl) 1 oxaspiro[4.5]dec 8 yl]benzeneacetamide; dpdpe; d-ala2; glu4]deltorphin antinociception; opioid δ receptor subtypes; deltorphin[2 dextro alanine 4 glutamic acid]
Journal Title: Life Sciences
Volume: 55
Issue: 2
ISSN: 0024-3205
Publisher: Elsevier Inc.  
Date Published: 1994-01-01
Start Page: PL-37
End Page: PL-43
Language: English
DOI: 10.1016/0024-3205(94)90110-4
PROVIDER: scopus
PUBMED: 8015351
DOI/URL:
Notes: Export Date: 14 January 2019 -- Article -- CODEN: LIFSA C2 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gavril W Pasternak
    414 Pasternak